To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

AAN conference featured the latest research and developments in neurological disorders like Alzheimer's disease, epilepsy and ...

Campaigners have called for a change in the way treatments for dementia are assessed in the wake of the decision on the drug ...

A good rule of thumb for protecting your brain health? If a neurologist wouldn’t do it, you probably shouldn’t either.

Biogen (NasdaqGS:BIIB) appointed multiple co-lead underwriters for two fixed-income offerings totaling over $1 billion, showcasing its efforts to bolster financial offerings. This move, coupled with ...

Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high.

The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China, and Japan gave a green light to ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

BioArctic AB (publ) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System Atrophy (MSA) patients for treatment with the alpha-synuclein antibody ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...